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ABSTRACT  59 
Background & Aims 60 
Guidelines regarding thromboprophylaxis for venous thromboembolisms (VTE) in children 61 
with inflammatory bowel disease (IBD) are based on limited paediatric evidence. We aimed 62 
to prospectively assess the incidence of VTE in paediatric-onset IBD (PIBD), characterize 63 
PIBD patients with VTE, and identify potential IBD-related risk factors. 64 
 65 
Methods 66 
From October 2016 till September 2020, paediatric gastroenterologists prospectively replied 67 
to the international Safety Registry, monthly indicating whether they had observed a VTE 68 
case in a patient <19 years with IBD. IBD details (type, Paris classification, clinical and 69 
biochemical disease activity, treatment) and VTE details (type, location, treatment, outcome) 70 
were collected. To estimate the VTE incidence, participants annually reported the number of 71 
PIBD patients, data source and catchment area of their center. A systematic literature review 72 
and meta-analysis was performed to calculate the VTE incidence in the general paediatric 73 
population.  74 
 75 
Results 76 
Participation of 129 PIBD centers resulted in coverage of 24,802 PIBD patients. Twenty 77 
cases of VTE were identified (30% Crohn’s disease). The VTE incidence was 3.72 [95%CI 78 
2.27 – 5.74] per 10,000 person-years, 14-fold higher than in the general paediatric population 79 
(0.27 [95%CI 0.18-0.38], p<0.001). Cerebral sinus venous thrombosis was most frequently 80 
reported (50%). All but one patient had active IBD, 45% were using steroids and 45% 81 
hospitalized. No patient received thromboprophylaxis, whereas according to current PIBD 82 
guidelines, this was recommended in 4/20 patients. 83 
 84 
Conclusion 85 
There is an increased risk of VTE in the PIBD population compared to the general paediatric 86 
population. Awareness of VTE occurrence and prevention should be extended to all PIBD 87 
patients with active disease, especially those hospitalized. 88 
  89 
INTRODUCTION 90 
Background 91 
Venous thromboembolic event (VTE) is a severe complication that may occur in paediatric 92 
patients with inflammatory bowel disease (IBD). It includes deep venous thrombosis (DVT) of 93 
the upper and lower extremity or central vasculature, pulmonary embolism (PE), cerebral 94 
sinus venous thrombosis (CSVT) and renal vein thrombosis. Population-based studies in the 95 
general paediatric population have reported annual incidences of 0.07 to 0.49 per 10.000 96 
children, with higher incidences in neonates and adolescents1-6. In hospitalized children this 97 
incidence may be increased, with reported incidences of 19 to 58 per 10.000 admissions5,7-10. 98 
VTE in children is associated with high mortality2,5,6 and may result in significant morbidity, 99 
such as persistent or recurrent thrombosis, post-thrombotic syndrome or persistent 100 
neurologic deficits due to CSVT11. In addition, VTE in hospitalized children with IBD is 101 
associated with increased likelihood of intensive care unit stay and accompanied with 102 
increased adjusted total costs12. 103 
Population-based studies have shown adults with IBD are at increased risk of developing 104 
VTE13-16. Few studies reported an increased risk for development of VTE in children with IBD, 105 
especially in those hospitalized15,17-21. However, most studies are based on retrospective 106 
studies involving billing or hospital databases, or report limited paediatric data.  107 
Risk factors are present in over 90% of paediatric VTE cases, including central venous 108 
catheter (CVC), surgery, immobility and infection5,22-25. In adult patients with IBD, active 109 
disease, fistulising or stenosing disease behaviour, extensive colonic involvement, 110 
Clostridium difficile infection, corticosteroid use, surgery and recent hospitalization are 111 
associated with increased VTE risk14-16,26-30. Interestingly, hospitalized adult patients with IBD 112 
have a 1.5 to 2-fold higher VTE risk than hospitalized adult patients without IBD14,27. 113 
However, little is known about the IBD-related risk factors associated with VTE in paediatric 114 
IBD (PIBD) patients. 115 
There are conflicting recommendations regarding thromboprophylaxis in current guidelines 116 
for adults and children with IBD, as summarized in Supplemental Table 131-33. The 117 
ESPGHAN guideline only recommends thromboprophylaxis for hospitalized children with 118 
acute severe colitis (ASC), with at least one additional VTE risk factor. Contrarily, this is not 119 
supported by the consensus statements of the Canadian Association of Gastroenterology, 120 
which recommends against VTE prophylaxis in hospitalized children with IBD, even if 121 
hospitalizations are related to severe IBD flares34. No recommendations exist for children 122 
with Crohn’s disease (CD). For adults with IBD, VTE prophylaxis is recommended during all 123 
hospitalizations according to some guidelines34,35, whereas according to other guidelines only 124 
in hospitalized patients with ASC36-38. These conflicting recommendations demonstrate that 125 
convincing evidence regarding incidence and risk factors of VTE and safety and efficacy of 126 
thromboprophylaxis in paediatric IBD patients is lacking. 127 
We aimed to establish the first international prospective cohort study of VTE in paediatric IBD 128 
patients, allowing us to examine and quantify the incidence of VTE in this population, for 129 
comparison with the general paediatric population. We aimed to examine the clinical 130 
phenotype and risk factors in cases reported. We hypothesized there would be an increased 131 
incidence of VTE in PIBD with active disease as the most likely risk factor. 132 
 133 
METHODS 134 
PIBD-SETQuality Safety Registry 135 
The PIBD-SETQuality Safety Registry is an international, prospective, electronic registry of 136 
rare and severe complications in children and adolescents with IBD, established by PIBD-NET. 137 
A list of ten rare but severe complications, including VTE, was established based on current 138 
literature and clinical expertise by a team of PIBD experts (Supplemental Table 2). In October 139 
2016, the registry was initiated in the Netherlands and the United Kingdom and in following 140 
years extended to other countries. Every month, participating physicians are requested via an 141 
electronic invite (E-card) to report whether any of the listed complications occurred in a PIBD 142 
patient under their care in the last month. Participants were asked to actively report the 143 
absence of a complication. To minimize the risk of selection bias, participants who did not 144 
respond to the survey received a maximum of nine reminders in three months. In addition to 145 
the monthly E-card, participants annually received a survey to collect information including; the 146 
number of PIBD patients under their care,  whether this number was based on a local database 147 
or estimated, and at what age children with IBD were transferred to adult care. In this annual 148 
survey, participants also reported the catchment area for referrals, based on well-defined 149 
geographical regions (Supplemental Methods)39. Based on these defined geographical 150 
regions, overlap in claimed areas could be examined.  151 
 152 
For each complication a follow-up form was designed and sent out automatically following the 153 
report of a complication to collect information on the IBD and the complication. IBD 154 
characteristics collected included year of diagnosis, IBD type (CD, ulcerative colitis (UC) or 155 
IBD unclassified (IBD-U)), Paris classification, clinical and biochemical disease activity, and 156 
treatment (details in Supplemental Methods). 157 
 158 
Venous thromboembolisms 159 
For VTEs specifically, inclusion criteria were; 1) diagnosis of IBD according to the revised Porto 160 
criteria40, 2) age <19 years at VTE diagnosis, 3) occurrence of a first VTE between September 161 
2016 and August 2020. A VTE was defined as a radiologically confirmed thromboembolism 162 
and categorized as extremity DVT (upper or lower), cerebral venous sinus thrombosis (CSVT), 163 
renal vein thrombosis or right intra-cardiac thrombosis. For each case the following additional 164 
information was collected: VTE type and location, presenting symptoms, history of VTE, 165 
presence of thrombophilia and VTE risk factors, antithrombotic treatment and prophylaxis and 166 
outcome (details in Supplemental Methods).  167 
 168 
Data extraction 169 
Data were extracted from the online registry on the 30th of September 2020. Duplicates were 170 
excluded by checking responder, centre, sex, year and month of birth, and date of VTE 171 
diagnosis. All data were anonymously collected using unique electronic links for each 172 
participant. The data was submitted by the participants using REDCap electronic data capture 173 
system and stored on secured Queen Mary University of London servers.  174 
 175 
Incidence data 176 
The incidence was calculated by the total number of IBD patients that developed a VTE divided 177 
by the number of PIBD patient-years in the registry (Supplemental Methods). If participants did 178 
not respond to the E-card three consecutive months, they were considered inactive during that 179 
time period and this period was thus not included in the calculation of patient-years. To account 180 
for possible inaccuracies in reporting of the PIBD population, we performed a sensitivity 181 
analysis including only those centers using robust local databases. We also performed a 182 
sensitivity analysis where we included the inactive months of participants. Since some centers 183 
had more than one reporting physician, the incidence calculations were done on a center level. 184 
 185 
Meta-analysis on incidence of VTE in general paediatric population 186 
A systematic literature review was performed to identify studies examining the incidence rate 187 
of VTE in the general paediatric population. Databases searched were Ovid Medline and 188 
Embase. A detailed search strategy and inclusion criteria are provided in the Supplemental 189 
Methods. Titles and abstracts were screened by two independent reviewers (MA and RK) and 190 
inconsistencies on inclusion were resolved by consensus. Extracted data included VTE 191 
incidence rate, sample size, total VTE number, duration of follow-up and number of patient-192 
years. Studies were included in the meta-analysis if the number of patient-years was reported 193 
or could be calculated based on sample size and duration of follow-up. A random effects model 194 
was used to compensate for heterogeneity (I2) across studies41.  195 
 196 
Statistical analysis 197 
Continuous variables are presented as median (IQR), rates as percentages (95%CI). 198 
Proportions were compared using Chi square tests or Fisher’s exact tests for smaller samples. 199 
Medians between groups were compared with the Mann-Whitney U test. For the meta-200 
analysis, the heterogeneity between studies was assessed with the I-square statistic. The 201 
incidence and 95% confidence intervals were calculated based on the total number of VTE 202 
cases and patient-years using the normal approximation to the binomial distribution.  203 
 204 
To estimate the relative risk of VTE development in the hospitalized compared to the non-205 
hospitalized PIBD patients, we calculated the rate of VTE events in the two groups individually. 206 
The denominator for the hospitalized group is the number of inpatient days while for the non-207 
hospitalized group it is the number of outpatient days. The expected number of inpatient days 208 
for the PIBD population in our study is a product of the total study population (in patient-days) 209 
and the inpatient days rate. This inpatient days rate was calculated using the PIBD population 210 
in the US as a reference. The reported prevalence rates of PIBD by Ye et al.42 and the total 211 
number of children (3-17 years) registered in the US in 202043 were used to estimate that the 212 
total PIBD population in the US is 47,319 patients. This corresponds to 17,283,113 patient-213 
days annually. Based on the length of stay and number of PIBD admissions in the US44, the 214 
total annual inpatient PIBD days in the US is 25,281. Therefore, according to the US literature, 215 
a PIBD patient is expected to spend 1.46 in every 1000 days in the hospital (0.146%).  216 
 217 
The proportions of UC/IBD-U and CD patients within the VTE cohort were compared to the 218 
proportions of UC/IBD-U and CD patients in the general PIBD population with a one-sample 219 
proportion test, using the EUROKIDS cohort, a representative large international cohort study, 220 
as a reference45. All test statistics were two-sided and a p-value <0.05 was considered 221 
statistically significant. Data analyses were performed with IBM SPSS version 25 (Armonk, 222 
NY, USA) or R version 4.0.2. 223 
 224 
Ethical statement  225 
This study was first approved by the ethics committee of Erasmus Medical Centre in the 226 
Netherlands and then conducted as required by local ethical committees. Data security 227 
agreements were signed with participating centers if required by national legislation.  228 
 229 
RESULTS 230 
Cohort description and denominator data 231 
The PIBD-SETQuality Safety Registry currently has active participation of 149 PIBD 232 
specialists from 129 centres in 30 different countries (Supplemental Table 3).The PIBD 233 
population under their care is 24,802 patients. The median duration of active participation in 234 
the Safety Registry was 2.2 years per participating center (IQR 0.92-3.70). The continuously 235 
increasing covered population in combination with the duration of each center’s participation, 236 
resulted in 53,762 PIBD patient-years of follow-up.  237 
 238 
Systematic review and meta-analysis of VTE incidence in children 239 
Electronic search results are presented in the Preferred Reporting Items for Systematic 240 
Reviews and Meta-Analysis (PRISMA) diagram (Figure 1). Study characteristics of fourteen 241 
included studies are presented in Supplemental Table 4. Meta-analysis of ten studies 242 
including VTE in general resulted in a pooled incidence rate of 0.27 (95%CI 0.18 – 0.38, I2 243 
99.7%) per 10,000 person-years in the general paediatric population (Figure 2). Data of six 244 
studies specifically describing CSVT resulted in a pooled incidence rate for CSVT of 0.045 245 
(95%CI 0.025 – 0.070, I2 94.1%) per 10,000 person-years in the general paediatric 246 
population (Figure 3).  247 
 248 
Incidence of VTE in PIBD patients 249 
During the time of follow-up, 21 cases of first VTE diagnosis in PIBD patients were reported. 250 
One case of a CSVT was excluded, because there was too little information to exclude 251 
duplicate reporting. We identified no other duplicates. The 20 remaining cases resulted in an 252 
incidence of 3.72 per 10,000 patient-years (95%CI 2.27 – 5.74). The VTE incidence in the 253 
PIBD population included in this study is thus 13.8 times higher (95%CI 8.8 – 21.7) than the 254 
pooled incidence rate in the general paediatric population (3.72 vs. 0.27; p<0.001). Ten 255 
cases were CSVTs, resulting in an incidence of 1.86 per 10,000 patient-years (95%CI 0.71 – 256 
3.01), 41.3 times higher (95%CI 20.8 – 82.0) than the pooled incidence rate of CSVT in the 257 
general paediatric population (1.86 vs. 0.045; p<0.001).  258 
Sensitivity analysis 259 
Sensitivity analysis only using cases (n=13) and denominator data (n=26,611) from centers 260 
that reported the total number of PIBD patients under their care based on robust local 261 
databases, resulted in an estimated incidence of 4.89 per 10,000 patient-years (95%CI 2.60 262 
– 8.35). When calculating the patient-years without excluding the inactive period of at least 263 
three consecutive months, the number of patient-years was 55,001. Using this denominator 264 
data, the estimated VTE incidence is 3.6 per 10,000 patient-years (95%CI 2.22 – 5.62) and 265 
the estimated CSVT incidence is 1.82 per 10,000 patient-years (95%CI 0.87 – 3.34). 266 
 267 
VTE risk ratio in outpatient versus hospitalized patients 268 
After applying the expected inpatient days rate (0.146%), on our study population of 53,762 269 
patient-years, we estimated that the Safety Registry patients would have spent 28,723 out of 270 
the 19,636,571 patient-days in the hospital. Given that 9 VTE events occurred during 271 
admission and 11 outside the hospital, the estimated VTE incidence for  hospitalized PIBD 272 
patients is 1144 (95%CI 523 - 2173) per 10,000 patient-years while the estimated VTE 273 
incidence for outpatient PIBD patients is 2.05 (95%CI 1.02 – 3.66) per 10,000 patient-years. 274 
Therefore, the estimated relative risk of developing a VTE in inpatients compared to 275 
outpatients is 559 (231 – 1348). 276 
 277 
Patient Characteristics 278 
In all cases, detailed patient characteristics and disease specifics were available. The 279 
median age at VTE occurrence was 13.6 years (IQR 9.6-16.1) of which 8 children (40%) 280 
were diagnosed <12 years of age. The median IBD duration was 7.9 months (IQR 0.3-20.5) 281 
(Table 1). Eight VTEs (38%) presented within 2 months of IBD diagnosis of which 6 (30%) 282 
were at the time of first diagnosis. Fourteen out of 20 cases occurred in children with 283 
UC/IBD-U, all with pancolitis. All CD patients had colonic or ileocolonic disease. There were 284 
no statistically significant differences between patients with CD and UC/IBD-U concerning 285 
age at IBD diagnosis, age at VTE diagnosis or IBD duration prior to VTE diagnosis. 286 
Compared to the percentage of UC patients in a large European cohort characterizing PIBD 287 
patients (EUROKIDS study) (32%), the percentage of UC patients within the VTE cohort 288 
(55%) was significantly higher (p=0.03).  289 
 290 
VTE specifics 291 
In 50% of cases (n=10) a CSVT was reported, mostly involving multiple dural venous sinuses 292 
(Table 2). Presenting symptoms of CSVT included headache (n=8), seizures (n=3) and 293 
hemiparesis (n=2). Extremity DVTs were the second most reported VTE type (n=7). Three 294 
patients had a PE (two with a lower extremity DVT). One patient had a simultaneous cerebral 295 
arterial thrombosis and DVT. 296 
 297 
Risk factors 298 
No patient had a medical or family history of VTE. Both hereditary and acquired 299 
thrombophilia were tested in 70% of cases, but none were identified. In 65% of cases, one or 300 
more non-IBD risk factors were identified (Table 2). These included: steroids (45%, n=9), 301 
immobility (15%, n=20), central venous catheter (15%, n=3), parenteral nutrition (10% n=2) 302 
and surgery (10%, n=2). Nine out of 20 patients (45%) were diagnosed with the VTE during 303 
hospital admission, including eight IBD-related hospitalizations. 304 
 305 
IBD characteristics  306 
Most VTEs (90%) occurred during active disease. Of these 15/17 had moderate (n=7) or 307 
severe (n=8) disease activity (Table 3). Only two VTEs occurred while the patient’s disease 308 
was in clinical remission; one was receiving a steroid course and had a faecal calprotectin 309 
level of >6000 µg/g two months prior to the VTE, the other had a faecal calprotectin level of 310 
194 and presented with a CVC-related upper extremity DVT (Supplemental Table 5). In all 311 
other patients, faecal calprotectin levels around VTE diagnosis were >500 µg/g (median 312 
2100 µg/g, IQR 995 – 5615). Blood results around VTE diagnosis show active inflammation 313 
in most patients: 12/17 patients had an ESR >20 mm/hour or a CRP level >5 mg/L. Median 314 
platelet count was 458 x 109/L (IQR 268 – 637).  315 
 316 
IBD treatment 317 
Five (25%) patients were not receiving any IBD-related medication at the time VTE was 318 
diagnosed. In four of those, the IBD was diagnosed around the time of VTE diagnosis (Table 319 
3). Nine patients (45%) were on steroids, in some cases combined with other IBD-related 320 
treatments. 321 
 322 
VTE prophylaxis 323 
No patients were using anti-thrombotic prophylaxis prior to the event. In retrospect, based on 324 
the most recent ESPGHAN guidelines, only 4/20 cases would have fulfilled the criteria for 325 
thromboprophylaxis (Table 2).31-33 326 
 327 
VTE treatment  328 
The majority of patients (80%) were treated with low molecular weight heparin (LMWH) 329 
(Supplemental Table 6). One CSVT patient with a haemorrhagic stroke, received no anti-330 
thrombotic therapy. Anti-thrombotic treatment complications were reported in four patients 331 
and were all IBD-related gastrointestinal bleeds; two non-major bleedings and two minor 332 
bleedings. Following the VTE event, 8/20 patients received long term antithrombotic 333 
prophylaxis after antithrombotic therapy was ceased. 334 
 335 
VTE outcome 336 
Sixteen out of 20 patients fully recovered from their VTE. Two CSVT patients died 337 
(Supplemental Table 6). One CSVT patient, who needed a craniotomy, experienced mild 338 
neurological impairment after recovery. One patient had a post-thrombotic syndrome with 339 
persisting leg swelling a few weeks after the VTE, but was lost to follow-up after two months. 340 
Two patients had recurrent VTE reported. One patient developed a DVT in the right femoral 341 
vein two weeks after the CSVT and a third VTE in the right popliteal vein one year after the 342 
first event, both while on antithrombotic prophylaxis. The other patient had a second and 343 
third DVT around six and 10 months, respectively, after the first DVT.  344 
 345 
DISCUSSION 346 
This is the first prospective, international cohort study reporting data on VTEs in paediatric 347 
IBD. With a cohort of almost 25,000 patients, this study covered a larger population than any 348 
previous study. The set-up of this study enabled us to collect data about rare events from 349 
multiple countries in a homogeneous manner, resulting in 20 well-described VTE cases.  350 
The results show that PIBD patients have a nearly 14-fold higher VTE risk compared to the 351 
general paediatric population. Previously, studies in adults have reported a 1.5 to 3-fold 352 
increased incidence in IBD patients15,46-48, regardless of IBD type46. A Danish population 353 
based study, showed that the relative risk is higher in children and adolescents and 354 
decreases with increasing age15. This study found an incidence rate of 8.9 per 10,000 355 
person-years in IBD patients within the age group 0-20 years and a relative risk of 4.5 (1.7-356 
12.0) compared to non-IBD patients. A recently published Canadian population-based study 357 
demonstrated that the 5-year incidence of VTE in PIBD patients was 31.2 (23.7 – 41.0) per 358 
10,000 person-years21. This is almost 10 times higher than in our study. However, the 359 
absolute number of VTE cases in their study is not reported and they only included newly-360 
diagnosed IBD patients, which are probably the ones being most at risk, as supported by the 361 
fact that the 1-year incidence was 81.2 per 10,000 person-years. Despite these differences in 362 
incidence between the studies, all suggest an increased risk of VTE in PIBD patients.    363 
  364 
In another study, Nylund et al. used the inpatient billing codes in the US to assess the risk of 365 
developing VTE and reported an absolute risk of 117.9 per 10,000 hospitalizations for 366 
children with IBD compared to 50.4 per 10,000 hospitalizations for children without IBD18. 367 
Similarly, we show that the risk in the hospitalized PIBD population is 559 times higher than 368 
in the outpatient PIBD population. It should be taken into consideration that this relative risk 369 
was calculated using hospitalization data from the United States, which could be different 370 
than hospitalization rates in Europe.  371 
 372 
An interesting finding considering the larger proportion of CD patients within the PIBD 373 
population is the majority of UC/IBD-U cases in our cohort45. A large study in adults with IBD 374 
found a 1.32 times greater prevalence among UC patients than CD patients27. Saleh et al, also 375 
found that the relative risk, compared to non-IBD patients, was higher in UC (RR 1.13) than in 376 
CD patients (RR 1.08)47. Contrarily, the Danish population-based study reported a higher risk 377 
in patients with CD than those with UC15. However, the proportion of UC patients (71%) within 378 
their IBD population was remarkably high, which may contribute to their high reported 379 
incidence. Disease location in CD was not described in their study, but based on our findings 380 
colonic disease may play a role in VTE risk of those patients.  381 
 382 
Although thrombophilia may be a risk factor of VTE in adult IBD patients, it does not seem an 383 
important one in children49. None of the patients in our cohort had acquired or hereditary 384 
thrombophilia. This is in contrast with a retrospective study in PIBD patients describing 385 
thrombophilia in 4 out of 9 (44%) VTE cases17. Studies investigating the prevalence of inherited 386 
thrombophilia in children with VTE, also reported lower rates (12-15%)50-52. 387 
 388 
In our study all but one patient had active inflammation. Studies in adult IBD patients showed 389 
that the risk of VTE is increased at the time of a disease flare14,29,53. Although the aetiology of 390 
VTE in patients with IBD is likely to be multifactorial, accumulating evidence exists that the 391 
presence of systemic inflammation triggers a hypercoagulable state54,55. This is supported by 392 
the fact that some other pro-inflammatory conditions are more commonly associated with 393 
development of hospital-acquired VTE in paediatric patients, such as cystic fibrosis, childhood 394 
cancer and systemic infection56-59. Interestingly, three cases involved VTEs at multiple 395 
locations, supporting the theory that systemic in addition to local factors contribute to thrombus 396 
formation60.  397 
 398 
In addition to active disease, the most common risk factors in our PIBD cohort were steroid 399 
use and presence of a CVC. Nylund et al. performed a multivariate analysis in patients aged 400 
5-20 years and identified older age, CVC, parenteral nutrition and an identified 401 
hypercoagulable condition as risk factors, without further defining the term hypercoaguable 402 
condition18. Notably, steroid use was not included in this analysis. Findings from a meta-403 
analysis showed that systemic corticosteroid use was associated with a 2.2 times higher rate 404 
of VTE compared to IBD patients without steroid medication61.  405 
 406 
Remarkably, 50% of VTE cases in our study concerned a CSVT, resulting in a 46-fold higher 407 
incidence than in the general paediatric population. This is of particular interest considering 408 
the 20% mortality rate in children with CSVT in our cohort and known high rates of persisting 409 
neurologic deficits (17-79%) of CSVT in children62. In a systematic review by Lazzerini et al., 410 
50/92 cases of arterial and venous thromboembolisms in children with IBD were cerebral63. 411 
This is higher than the CSVT rate in adult IBD patients (4.5%) or the general paediatric 412 
population (10.8%)6,64. A possible contributing factor to the large proportion of CSVT in our 413 
cohort could be corticosteroid use, as this is also a contributing factor in children with acute 414 
lymphatic leukaemia, who have a 2-6% risk of CSVT.65,66 However, as only 45% of CSVT 415 
patients in our cohort were on corticosteroids, the aetiology behind the specific cerebral 416 
location remains unexplained.  417 
 418 
An important strength of our study is the reporting by the physicians themselves, which led to 419 
solid and detailed information about every patient that developed a VTE. Another strength is 420 
the prospective set-up in which physicians report cases within the month of occurrence of the 421 
VTE. Physicians need to actively report the absence of a VTE case every month. The risk of 422 
selection bias in case reporting is further minimized by actively chasing participants who did 423 
not respond to the monthly survey. We are the first to report an incidence of VTE in children 424 
and adolescents with IBD based on a prospective registry. Available studies in children thus 425 
far have reported increased incidences based on retrospective billing data bases or ICD-9 and 426 
ICD-10 coding, which has limitations67. Reporting by the physicians themselves led to solid 427 
and detailed information about every patient that developed a VTE. Although the collection of 428 
denominator data via the reporting physician could have led to less precise estimates of the 429 
denominator, as not in every hospital registries of new and current IBD patients might be up to 430 
date, the sensitivity analysis we performed confirmed the higher incidence rate compared to 431 
the general paediatric population. Moreover, given the large number of participating centers, 432 
we expect any inaccuracies in over- or underreporting to level out, thereby not influencing our 433 
findings significantly. 434 
 435 
One of the limitations of our study is that our data does not include full coverage of entire 436 
countries, but relies on clearly defined geographical catchment areas reported by the local 437 
investigators. This could have introduced heterogeneity, as depending on the country or region 438 
patients might be referred from other centers to tertiary centers for specialized care and there 439 
could be overlap in patients covered by each center. A second limitation is the transition from 440 
paediatric to adult care between 14 and 19 years of age in some centers, which could be the 441 
explanation of the relatively young age of our VTE cohort. This could have resulted in less 442 
precise estimates, as we expect the incidence to be higher with increasing age. However, the 443 
majority of centers (68%) treat their patients up to the age limit of 18. A third limitation of this 444 
study is the inability to perform a multivariate analysis on the risk factors of developing a VTE. 445 
Despite the large cohort, the small number of patients with a VTE and the lack of a control 446 
group prevents such an analysis. Considering this low number of cases was found after three 447 
years of international case collection, including a large coverage of 24,802 children and 448 
adolescents with IBD, this shows that the absolute number of VTE cases in paediatric IBD 449 
patients is low.  450 
 451 
According to the ECCO guideline, prophylaxis is recommended in adult IBD patients if they 452 
are hospitalized, regardless of indication34. In our cohort, 11/20 patients developed a VTE while 453 
not hospitalized. A survey among 162 paediatric gastroenterologists showed that physicians 454 
are hesitant to provide thromboprophylaxis for children with IBD because of lack of clear 455 
paediatric guidelines68. Safety concerns, specifically the presumed bleeding risk, are the main 456 
reason for paediatric and adult gastroenterologists to be cautious about prescribing 457 
prophylactic anticoagulation68,69. A systematic review assessing safety and efficacy of 458 
thromboprophylaxis in children, showed that major bleeding events occurred in only 0.6% of 459 
children (some in neonates)70. Studies in children are lacking, but in adults with IBD 460 
thromboprophylaxis with LMWH has shown to be safe, even in patients who initially present 461 
with rectal bleeding71,72. In future, direct oral anticoagulants may replace the use of LMWH as 462 
thromboprophylaxis in children with VTE, because of the advantage of oral over subcutaneous 463 
administration and fewer bleeding complications73.  464 
 465 
The current treatment guideline for children with ASC suggests to only administer VTE 466 
prophylaxis in pubertal children with at least one other risk factor and in prepubertal children 467 
with two other risk factors31. This age discrimination is suggested because of limited data on 468 
safety and efficacy of thromboprophylaxis in prepubertal children74, not on differences in VTE 469 
risk. In our cohort, 40% of the reported cases occurred in children below 12 years of age, 470 
indicating that prepubertal children are at least equally at risk.  471 
 472 
Interestingly, findings from a recent British panel of gastroenterologists in the context of the 473 
COVID-19 pandemic show that prophylactic anticoagulation was deemed appropriate in all 474 
paediatric patients with ASC, thus fitting the guidance of an extra risk factor75. We found that 475 
four cases should have received prophylaxis if following the recently published paediatric ASC 476 
guideline31. However, in seven other UC cases, despite the presence of ASC in some, 477 
prophylaxis was not suggested because of the absence of extra risk factors. 478 
 479 
With this increased risk of VTE in paediatric IBD patients, especially in those hospitalized, and 480 
potentially negative outcomes in paediatric IBD patients, we would advise to consider 481 
thromboprophylaxis for all hospitalized patients with active UC/IBD-U, regardless of age or 482 
presence of additional VTE risk factors, and for all hospitalized children with moderate-to-483 
severe CD with at least one additional VTE risk factor. Further prospective studies are 484 
necessary to assess safety of prophylaxis in paediatric IBD patients, especially in outpatients 485 
with active disease.  486 
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  718 
FIGURE LEGENDS 719 
Figure 1. PRISM flow chart 720 
Flow diagram of the systematic literature search on the incidence of venous thromboembolism in the 721 
general paediatric population. * Reasons for exclusion included: did not report on a pediatric 722 
population (n = 4); did not provide data to calculate incidence rates (n = 5); no population-based 723 
study (e.g. only hospital-associated VTE) (n = 2); incidence rates reported per number of hospital 724 
admissions (n = 3); no original article (n = 4); not available in full-text (n = 2). 725 
 726 
Figure 2. Meta-analysis incidence VTE in general paediatric population 727 
Findings of the meta-analysis data regarding the incidence of VTE in the general paediatric 728 
population. VTE: venous thromboembolism. 729 
 730 
Figure 3. Meta-analysis incidence CSVT in general paediatric population 731 
Findings of the meta-analysis data regarding the incidence of CSVT in the general paediatric 732 
population. CSVT: cerebral sinus venous thrombosis.  733 
 734 
 735 
  736 
TABLES 737 
Table 1. Patient characteristics 738 







Sex (n, % male) 1 (16.7)  7 (50.0)  8 (40.0) 0.01 
Body mass index SDS 
(median, IQR) 
0.38 (-0.85-0.55) -0.44 (-2.3-0.49) -0.43 (-1.7-0.53) 0.40 
Age at IBD diagnosis, 
years (median, IQR) 
11.6 (8.5-15.1) 12.9 (7.6-14.8) 12.2 (7.8-14.9) 0.90 
Age at VTE diagnosis, 
years (median, IQR) 
13.5 (9.1-16.1) 13.7 (9.3-16.3) 13.7 (9.6-16.1) 1.00 
IBD disease duration prior 
to VTE diagnosis, months 
(median, IQR) 
1.7 (0.2-28.7) 9.6 (1.9-23.8) 8.4 (0.4-20.5) 0.32 
Paris classification at 
latest assessment 


























  739 
Table 1. Patient characteristics depicted per IBD diagnosis. Comparisons between CD and 740 
UC/IBDU patients were performed with the Mann-Whitney U test for continuous variables and the Chi-741 
square or Fisher’s exact test for categorical variables. * P-values are for comparison of CD vs. 742 
UC/IBD-U. IBD: inflammatory bowel disease; VTE: venous thromboembolism; CD: Crohn’s disease; 743 
UC: ulcerative colitis; IBD-U: IBD unclassified; GI: gastrointestinal; DVT: deep venous thrombosis; 744 
SVC: superior vena cava; IVC: inferior vena cava; CSVT: cerebral sinus venous thrombosis; n/a: not 745 
applicable.746 
Table 2. Type of venous thromboembolism and presence of risk factors 747 
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prophylaxis according to 
ECCO/ESPGHAN guidelines 
 Intracranial, n=11            
1 
Multiple venous sinuses and left 
internal jugular vein 
M UC 7,6 7,6 White No None No¥ None No 
No guidance on prophylaxis in UC 
that is not ASC 
2 Superior sagittal sinus F UC 14,7 14,7 White No None No None No 
Does not fit criteria for 
consideration of prophylaxis (no 
additional risk factors) 
3 Multiple venous sinuses M CD 9,3 10,2 White No Steroids No None No No guidance on prophylaxis in CD 
4 
Multiple venous sinuses and 
proximal internal jugular vein 
F IBD-U 14,1 15,8 White Unknown Steroids No None No 
No guidance on prophylaxis in UC 
that is not ASC 
5 Multiple venous sinuses F CD 15,0 15,3 White No Steroids No None No No guidance on prophylaxis in CD 
6 Multiple venous sinuses M UC 2,1 2,3 SEA No# None Yes None No 
Does not fit criteria for 
consideration of prophylaxis (no 
additional risk factors) 
7 Dural venous sinus, unspecified F CD 11,6 18,3 
White/ 
SEA 
Unknown Steroids No None No No guidance on prophylaxis in CD 
8 Multiple venous sinuses M UC 16,7 16,7 White No Surgery Yes None No 
No guidance on prophylaxis in UC 
that is not ASC 
9 
Superior sagittal sinus and right 
femoral vein 
F CD 6,0 5,9 
White/ 
SEA 
Unknown None Yes None No No guidance on prophylaxis in CD 
10 Posterior sagittal sinus M UC 12,7 13,6 Mixed Unknown Steroids Yes None No 
Does not fit criteria for 
consideration of prophylaxis (no 
additional risk factors) 
 Lower extremity, n=8‡            
11 
Proximal medial gastrocnemius 
veins 
F CD 15,4 15,4 White No None Yes None No No guidance on prophylaxis in CD 
12 
Common femoral vein to 
popliteal vein 







Prophylaxis should be considered 
(adolescent girl with 1 risk factor) 
13 
Lower IVC, common iliac, 
femoral, superficial femoral vein 
M UC 15,0 16,2 White No None No None No 
No guidance on prophylaxis in UC 
that is not ASC 
14 Femoral and popliteal vein* F CD 11,6 11,6 White Unknown 
CVC, steroids, 
myocarditis 
Yes None No No guidance on prophylaxis in CD 





No additional risk factors, so 
prophylaxis not recommended 
 Upper extremity, n=1            







No guidance on prophylaxis in UC 
that is not ASC 
 Pulmonary, n=3            
17 
Subsegmental pulmonary 
embolus left lower lobe 








Prophylaxis should be considered 
(adolescent boy with 1 additional 
risk factors) 
18 
Proximal left pulmonary vein and 
IVC 
F UC 8,7 9,4 White No 
Steroids, sepsis, 
immobility 
Yes None No 
Prophylaxis should be considered 
(prepubertal girl with 2 additional 
risk factors) 
19 
(Sub)segmental bilateral lower 
lobe, left posterior tibial, 
peroneal and popliteal veins 




No None No 
No guidance on prophylaxis in UC 
that is not ASC 
 Other, n=1            







Yes None No 
Prophylaxis may be considered 
(prepubertal girl with 2 additional 
risk factors) 
 748 
Table 2. Type of venous thromboembolism and presence of risk factors. The column thrombophilia includes hereditary and acquired thrombophilia. # 749 
Hereditary thrombophilia was not tested. ** Acquired thrombophilia was not tested. ‡ Three patients had a lower extremity DVT occurring together with another 750 
VTE type. *This patient was diagnosed with an arterial thrombosis in the middle cerebral artery branches at the time of VTE diagnosis. ¥ This patient was 751 
discharged from an IBD-related hospital admission for two days at the time of VTE diagnosis. VTE: venous thromboembolism; IBD: inflammatory bowel 752 
disease; CD: Crohn’s disease; UC: ulcerative colitis; IBD-U: IBD unclassified; y: years; G6PD: glucose-6-phosphate dehydrogenase; CVC: central venous 753 
catheter; PSC: primary sclerosing cholangitis; IVC: inferior vena cava; SEA: South East Asian.754 
Table 3. IBD related characteristics at time of VTE diagnosis 755 
 756 
 757 
Table 3. IBD related characteristics at time of VTE diagnosis. Missing values for each variable 758 
were: PGA n = 1; Fcal n = 10; ESR n = 7; CRP n = 5; Haemoglobin n = 5; Platelet count n = 4; 759 
Leukocyte count n = 4. IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis; 760 
IBD-U: IBD unclassified; PGA: physician’s global assessment; ESR; erythrocyte sedimentation rate; 761 
CRP: C-reactive protein.  762 
 763 
 CD 
n = 6 (30%) 
UC/IBD-U 
n = 14 (70%) 
Total 

























Faecal calprotectin, µg/g 
(median, IQR) 
4050 (2100 – 6000) 1637 (985 – 5433) 2100 (995 – 5615) 
ESR, mm/hr 
(median, IQR) 
55 (3 – 68.5) 23 (18.5 – 49.5) 27.0 (18.0 – 56.0) 
CRP, mg/L  
(median, IQR) 
8.9 (1.8 – 49.0) 27.0 (12.0 – 84.0) 23.0 (3.9 – 60.0) 
Haemoglobin, mmol/L 
(median, IQR) 
5.7 (4.5 – 6.7) 5.7 (5.0 – 6.7) 5.7 (4.9 – 6.7) 
Platelet count, x 109/L 
(median, IQR) 
458 (261 – 468) 436 (268 – 679) 458 (268 – 637) 
Leukocyte count, x 109/L 
(median, IQR) 
10.2 (7.6 – 13.1) 12.3 (6.0 – 16.8) 11.7 (7.4 – 15.6) 
IBD treatment at time of 
VTE 
Corticosteroid use 
Anti-TNF agent use 
Immunomodulator use 
 
 
4 (67%) 
0 
3 (50%) 
 
 
5 (36%) 
4 (29%) 
3 (21%) 
 
